Virtus ETF Advisers LLC Seres Therapeutics, Inc. Transaction History

Virtus ETF Advisers LLC

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 07, 2023	SELL	$2.33 - $5.07 $3,755 - $8,172	-1,612 Reduced 9.07%	16,156 $38,000
Q2 2023 Aug 14, 2023	BUY	$4.67 - $6.55 $6,654 - $9,333	1,425 Added 8.72%	17,768 $85,000
Q1 2023 May 15, 2023	SELL	$4.95 - $6.09 $31,110 - $38,275	-6,285 Reduced 27.78%	16,343 $92,000
Q4 2022 Feb 14, 2023	SELL	$5.09 - $9.05 $81,775 - $145,397	-16,066 Reduced 41.52%	22,628 $126,000
Q3 2022 Nov 14, 2022	BUY	$3.5 - $7.2 $1,004 - $2,066	287 Added 0.75%	38,694 $248,000

Q2 2022 Aug 12, 2022	BUY	$2.7 - $7.62 $51,737 - $146,014	19,162 Added 99.57%	38,407 $132,000
Q1 2022 May 16, 2022	SELL	$6.3 - $8.84 $7,144 - $10,024	-1,134 Reduced 5.56%	19,245 $137,000
Q4 2021 Feb 14, 2022	BUY	$6.02 - $11.43 $60,723 - $115,294	10,087 Added 98.01%	20,379 $170,000
Q3 2021 Nov 15, 2021	SELL	$5.46 - $22.6 $2,921 - $12,091	-535 Reduced 4.94%	10,292 $72,000
Q2 2021 Aug 10, 2021	SELL	$18.46 - $24.36 $23,407 - $30,888	-1,268 Reduced 10.48%	10,827 $258,000
Q1 2021 May 17, 2021	BUY	$17.66 - $28.92 $3,602 - $5,899	204 Added 1.72%	12,095 $249,000
Q4 2020 Feb 12, 2021	BUY	$23.25 - $37.73 $276,465 - $448,647	11,891 New	11,891 $291,000
Q2 2018 Aug 10, 2018	SELL	$6.91 - $9.55 $530,086 - $732,609	-76,713 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$7.34 - $11.16 $304,008 - $462,224	41,418 Added 117.35%	76,713 $563,000
Q4 2017 Feb 14, 2018	BUY	$9.15 - $12.64 $27,623 - $38,160	3,019 Added 9.35%	35,295 $358,000
Q3 2017 Nov 14, 2017	BUY	$12.81 - $16.85 $37,815 - $49,741	2,952 Added 10.07%	32,276 $518,000
Q2 2017 Aug 14, 2017	BUY	N/A	29,324	29,324 $331,000

100

62.7M

36.9K

476K

Ticker MCRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,072,000
Market Cap $89.3M
Description
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.